Lactobacillus rhamnosus has long been known as the probiotic species for the prevention and treatment of eczema. However, strain specificity has not always been conclusive in collaborative research. A revolutionary set of clinical trials published in June 2013 now spanning six years have shown Lactobacillus rhamnosus HN001 in particular, to yield a high efficacy in preventing infant and childhood eczema, as well as effectively lowering atopic sensitisation.
A double-blind randomised placebo controlled trial was conducted on 425 high risk infants (diagnosis of allergic disease present in either parent) born to mothers who were administered L. rhamnosus HN001 from 35 weeks gestation up until the infant reached 6 months of age for nursing mothers, and direct infant supplementation from birth until the age of 2.
At 2 years of age infants receiving the supplementation had a dramatic 50% reduction in eczema prevalence.
At 4 years of age, 2 years after the treatment ceased, this positive effect continued to persist in the infants.
At 6 years of age, 4 years after probiotic supplementation was discontinued, a monumental 40% decline in cumulative prevalence in eczema persisted, alongside a 30% reduction of developing atopic sensitisation.